• Record quarterly revenue exceeding A$100,000
• Repeat cartridge orders across multiple regions, validating clinical adoption
• Secured ~A$1.4M+ in multi-year contracted revenue across Europe and MENA

Memphasys Limited has delivered a strong performance in the March 2026 quarter, reflecting the effective execution of its strategic realignment. The Company has transitioned from a research-led organization to a commercially driven enterprise, with a focus on the commercialization of the Felix™ System. Key achievements include the generation of meaningful recurring revenue across multiple geographic markets, the establishment of repeat cartridge ordering behavior, and the attainment of regulatory approvals in key markets such as Europe, the UK, and Australia. Memphasys has also advanced its commercial pathways in India and maintained cost discipline while redirecting capital toward high-impact commercial activities. The Company has now progressed beyond strategy articulation and is demonstrating execution in-market, with early indicators supporting the development of a scalable recurring revenue model. Memphasys is now positioned to transition from initial commercial validation to scaled execution, with a focus on expanding its base of active, revenue-generating clinics, increasing repeat orders, and scaling commercial activity across Europe and the Middle East and North Africa (MENA) region.

Memphasys expects continued growth in revenue over the coming quarters, with increasing contribution from recurring cartridge usage.

Memphasys is focused on expanding its base of active, revenue-generating clinics, increasing the frequency and volume of repeat orders, scaling commercial activity across Europe and MENA, advancing market entry in key regions like Australia, New Zealand and India, and continuing to optimize cost structures, manufacturing COGS and margins.